Fibrin-binding, peptide amphiphile micelles for targeting glioblastoma

Biomaterials

Volumn 35, Issue 4, 2014, Pages 1249-1256

  Chung, Eun Ji ^a   Cheng, Yu ^b   Morshed, Ramin ^b   Nord, Kathryn ^a   Han, Yu ^b   Wegscheid, Michelle L ^b   Auffinger, Brenda ^b   Wainwright, Derek A ^b   Lesniak, Maciej S ^b   Tirrell, Matthew V ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Brain; Diagnostic; Glioblastoma; Micelle; Self assembly; Targeting

Indexed keywords

CHEMOTHERAPEUTIC AGENTS; DIAGNOSTIC; ENHANCED PERMEABILITY AND RETENTION EFFECTS; GLIOBLASTOMAS; HISTOLOGICAL EVALUATION; INTRAVENOUS ADMINISTRATION; RETICULOENDOTHELIAL SYSTEMS; TARGETING;

AMINO ACIDS; BRAIN; DRUG DELIVERY; SELF ASSEMBLY; TUMORS;

MICELLES;

ALANINE; AMPHOPHILE; ARGININE; CYSTEINE; FIBRIN; GLUTAMIC ACID; LYSINE; PENTAPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; GLIOBLASTOMA; IMMUNOHISTOCHEMISTRY; MALE; MICELLE; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; TISSUE INJURY; ZETA POTENTIAL;

MUS;

BRAIN; DIAGNOSTIC; GLIOBLASTOMA; MICELLE; SELF-ASSEMBLY; TARGETING;

ANIMALS; BRAIN; BRAIN NEOPLASMS; CARBOCYANINES; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FIBRIN; GLIOBLASTOMA; MALE; MICE; MICE, INBRED C57BL; MICELLES; OLIGOPEPTIDES;

EID: 84888438033     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.10.064     Document Type: Article

References (35)

1. Preusser M., de Ribaupierre S., Wöhrer A., Erridge S.C., Hegi M., Weller M., et al. Current concepts and management of glioblastoma. Ann Neurol 2011, 70:9-21.
2. Stupp R., Hegi M.E., Mason W.P., van den Bent M.J., Taphoorn M.J., Janzer R.C., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10:459-466.
3. Ong B.Y.S., Ranganath S.H., Lee L.Y., Lu F., Lee H.-S., Sahinidis N.V., et al. Paclitaxel delivery from PLGA foams for controlled release in post-surgical chemotherapy against glioblastoma multiforme. Biomaterials 2009, 30:3189-3196.
4. Chang S.M., Kuhn J.G., Robins H.I., Schold S.C., Spence A.M., Berger M.S., et al. Aphase II study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants. Cancer 2001, 91:417-422.
5. Zhou J., Atsina K.B., Himes B.T., Strohbehn G.W., Saltzman W.M. Novel delivery strategies for glioblastoma. Cancer J 2012, 18:89-99.
6. Pardridge W.M. Drug targeting to the brain. Pharm Res 2007, 24:1733-1744.
7. Xin H., Sha X., Jiang X., Zhang W., Chen L., Fang X. Anti-glioblastoma efficacy and safety of paclitaxel-loading angiopep-conjugated dual targeting PEG-PCL nanoparticles. Biomaterials 2012, 33:8167-8176.
8. Gu G., Xia H., Hu Q., Liu Z., Jiang M., Kang T., et al. PEG-co-PCL nanoparticles modified with MMP-2/9 activatable low molecular weight protamine for enhanced targeted glioblastoma therapy. Biomaterials 2013, 34:196-208.
9. Kuo Y.-C., Liang C.-T. Inhibition of human brain malignant glioblastoma cells using carmustine-loaded catanionic solid lipid nanoparticles with surface anti-epithelial growth factor receptor. Biomaterials 2011, 32:3340-3350.
10. Zhang P., Hu L., Yin Q., Zhang Z., Feng L., Li Y. Transferrin-conjugated polyphosphoester hybrid micelle loading paclitaxel for brain-targeting delivery: synthesis, preparation and invivo evaluation. JControl Release 2012, 159:429-434.
11. Peer D., Karp J.M., Hong S., FaroKhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2:751-760.
12. Torchilin V.P. Micellar nanocarriers: pharmaceutical perspectives. Pharm Res 2007, 24:1-16.
13. Kedar U., Phutane P., Shidhaye S., Kadam V. Advances in polymeric micelles for drug delivery and tumor targeting. Nanomedicine 2010, 6:714-729.
14. Kabanov A.V., Gendelman H.E. Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Progress Polym Sci 2007, 32:1054-1082.
15. Gilmore J.L., Yi X., Quan L., Kabanov A.V. Novel nanomaterials for clinical neuroscience. JNeuroimmune Pharmacol 2008, 3:83-94.
16. Dvorak H.F. Rous-Whipple Award Lecture. How tumors make bad blood vessels and stroma. Am J Pathol 2003, 162:1747-1757.
17. Dvorak H., Senger D., Dvorak A., Harvey V., McDonagh J. Regulation of extravascular coagulation by microvascular permeability. Science 1985, 227:1059-1061.
18. Agemy L., Sugahara K.N., Kotamraju V.R., Gujraty K., Girard O.M., Kono Y., et al. Nanoparticle-induced vascular blockade in human prostate cancer. Blood 2010, 116:2847-2856.
19. Bardos H., Molnar P., Csecsei G., Adany R. Fibrin deposition in primary and metastatic human brain tumours. Blood Coagul Fibrinolysis 1996, 7:536-548.
20. Simberg D., Duza T., Park J.H., Essler M., Pilch J., Zhang L., et al. Biomimetic amplification of nanoparticle homing to tumors. Proc Natl Acad Sci U S A 2007, 104:932-936.
21. Peters D., Kastantin M., Kotamraju V.R., Karmali P.P., Gujraty K., Tirrell M., et al. Targeting atherosclerosis by using modular, multifunctional micelles. Proc Natl Acad Sci U S A 2009, 106:9815-9819.
22. Chattopadhyay A., London E. Fluorimetric determination of critical micelle concentration avoiding interference from detergent charge. Anal Biochem 1984, 139:408-412.
23. Nikanjam M., Gibbs A.R., Hunt C.A., Budinger T.F., Forte T.M. Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme. JControl Release 2007, 124:163-171.
24. Brem H., Piantadosi S., Burger P.C., Walker M., Selker R., Vick N.A., et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 1995, 345:1008-1012.
25. Kastantin M., Ananthanarayanan B., Karmali P., Ruoslahti E., Tirrell M. Effect of the lipid chain melting transition on the stability of DSPE-PEG(2000) micelles. Langmuir 2009, 25:7279-7286.
26. Alexis F., Pridgen E., Molnar L.K., Farokhzad O.C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008, 5:505-515.
27. Gu G., Gao X., Hu Q., Kang T., Liu Z., Jiang M., et al. The influence of the penetrating peptide iRGD on the effect of paclitaxel-loaded MT1-AF7p-conjugated nanoparticles on glioma cells. Biomaterials 2013, 34:5138-5148.
28. Hu K., Li J., Shen Y., Lu W., Gao X., Zhang Q., et al. Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: invitro and invivo evaluations. JControl Release 2009, 134:55-61.
29. Kobayashi H., Ogawa M., Alford R., Choyke P.L., Urano Y. New strategies for fluorescent probe design in medical diagnostic imaging. Chem Rev 2009, 110:2620-2640.
30. Duan X., Li Y. Physicochemical characteristics of nanoparticles affect circulation, biodistribution, cellular internalization, and trafficking. Small 2013, 9:1521-1532.
31. Arnida, Janát-Amsbury M.M., Ray A., Peterson C.M., Ghandehari H. Geometry and surface characteristics of gold nanoparticles influence their biodistribution and uptake by macrophages. Eur J Pharm Biopharm 2011, 77:417-423.
32. Sonavane G., Tomoda K., Makino K. Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size. Colloids Surf B Biointerfaces 2008, 66:274-280.
33. Dobrovolskaia M.A., Aggarwal P., Hall J.B., McNeil S.E. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm 2008, 5:487-495.
34. Longmire M., Choyke P.L., Kobayashi H. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine 2008, 3:703-717.
35. Choi H.S., Liu W., Misra P., Tanaka E., Zimmer J.P., Ipe B.I., et al. Renal clearance of quantum dots. Nat Biotechnol 2007, 25:1165-1170.